Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, Bartolini G, Matteucci L, Sullo FG, Debonis SA, Gallio C, Monti M, Valgiusti M, Muratore M, Rapposelli IG, Ulivi P, Frassineti GL. Passardi A, et al. Among authors: marisi g. Ther Adv Med Oncol. 2023 Dec 11;15:17588359231212184. doi: 10.1177/17588359231212184. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107830 Free PMC article.
Metastatic Colorectal Cancer.
Passardi A, Marisi G, Ulivi P. Passardi A, et al. Among authors: marisi g. Cancers (Basel). 2021 Dec 17;13(24):6346. doi: 10.3390/cancers13246346. Cancers (Basel). 2021. PMID: 34944966 Free PMC article.
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G, Azzali I, Passardi A, Rebuzzi F, Bartolini G, Urbini M, Canale M, Molinari C, Matteucci L, Sullo FG, Debonis SA, Gallio C, Gallo G, Frassineti GL, Ulivi P. Marisi G, et al. Sci Rep. 2023 Aug 9;13(1):12921. doi: 10.1038/s41598-023-40220-7. Sci Rep. 2023. PMID: 37558720 Free PMC article. Clinical Trial.
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
Urbini M, Marisi G, Azzali I, Bartolini G, Chiadini E, Capelli L, Tedaldi G, Angeli D, Canale M, Molinari C, Rebuzzi F, Virga A, Prochowski Iamurri A, Matteucci L, Sullo FG, Debonis SA, Gallio C, Frassineti GL, Martinelli G, Ulivi P, Passardi A. Urbini M, et al. Among authors: marisi g. JCO Precis Oncol. 2023 Sep;7:e2200694. doi: 10.1200/PO.22.00694. JCO Precis Oncol. 2023. PMID: 37656949
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D. Ulivi P, et al. Among authors: marisi g. J Transl Med. 2015 Aug 11;13:258. doi: 10.1186/s12967-015-0619-5. J Transl Med. 2015. PMID: 26259598 Free PMC article. Clinical Trial.
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial.
Casadei Gardini A, Carloni S, Scarpi E, Maltoni P, Dorizzi RM, Passardi A, Frassineti GL, Cortesi P, Giannini MB, Marisi G, Amadori D, Lucchesi A. Casadei Gardini A, et al. Among authors: marisi g. Oncotarget. 2016 Mar 1;7(9):10193-202. doi: 10.18632/oncotarget.7166. Oncotarget. 2016. PMID: 26848624 Free PMC article. Clinical Trial.
64 results